Vir Biotechnology, Inc. company information, Employees & Contact Information

Vir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD’s The Liver Meeting Business Wire

Study launches of VIR-5500 combined with ARPIs in mCRPC Urology Times

How Vir Bio CEO Marianne De Backer Is Rebuilding Commercial Momentum Citeline News & Insights

First subject dosed in Phase I trial of Vir Biotechnology’s VIR-5525 Clinical Trials Arena

Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2025 Financial Results on November 5, 2025 Business Wire

Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors Yahoo Finance

Vir Biotechnology Pivots to Cancer, Infectious Disease after Commercial and Clinical Setbacks Genetic Engineering and Biotechnology News

Vir's 'functional cure' candidate for hepatitis B misses mark in phase 2 Fierce Biotech

Vir Biotechnology, Inc. (VIR) Stock Analysis: Exploring The 197.96% Potential Upside DirectorsTalk Interviews

How Vir Biotechnology Inc. stock reacts to inflationary pressures - Rate Hike & Capital Protection Trade Alerts Trung tâm Dự báo KTTV quốc gia

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results Business Wire

Vir Biotechnology, Inc. (VIR): Among Stocks Under $10 that Will Triple Yahoo Finance

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results Business Wire

Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study Business Wire

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results Business Wire

Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta Business Wire

Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta Business Wire

Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta Yahoo Finance

Vir Leans Into Immunology Roots After Flamed-Out COVID Fame BioSpace

Evercore ISI initiates Vir Biotechnology stock with Outperform rating Investing.com

Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC Business Wire

Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTE PharmiWeb.com

Vir Biotechnology, Once a Hot Covid Stock, Finds New Path Forward in Cancer Barron's

Vir Biotechnology’s SWOT analysis: undervalued stock with potential in HDV and oncology Investing.com

Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates Yahoo Finance

Vir Biotechnology, Inc. (VIR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Yahoo Finance

Vir Biotechnology Catapults 58% On Promising Results In Cancer Treatment Investor's Business Daily

Dip Buying: Why Vir Biotechnology Inc. stock is considered a top pick - 2025 Market Overview & Smart Swing Trading Alerts Trung tâm Dự báo KTTV quốc gia

Vir Bio trims staff and pipeline to focus on Sanofi-licensed programmes Pharmaceutical Technology

Why Vir Biotechnology Inc. stock is considered a top pick - Trade Volume Report & Free Long-Term Investment Growth Plans Trung tâm Dự báo KTTV quốc gia

Vir Biotech August 2025 presentation: pipeline advances despite financial headwinds Investing.com

NGM Bio Announces Appointment of Wendy Yeh, M.D. as Chief Medical Officer GlobeNewswire

Earnings call transcript: Vir Biotech Q2 2025 results fall short, stock dips Investing.com

Why Vir Biotechnology, Inc. (VIR) Is Skyrocketing Now Yahoo Finance

Vir Biotechnology, Inc. (VIR) Stock Analysis: Exploring a 235% Potential Upside Amidst Challenges DirectorsTalk Interviews

Vir Biotechnology, Inc. (VIR) Stock Analysis: A 232% Potential Upside Beckons Investors DirectorsTalk Interviews

Vir Biotechnology: Catalysts Ahead In Hepatitis And Oncology (NASDAQ:VIR) Seeking Alpha

Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update Business Wire

Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Lags Revenue Estimates Nasdaq

Vir Biotechnology: Tobevibart Combination Pushing Forward For Needed HDV Treatment Seeking Alpha

Vir Biotechnology, Inc. (VIR) Stock Analysis: Unpacking a 254.66% Potential Upside in the Biotech Sector DirectorsTalk Interviews

Earnings call transcript: Vir Biotech beats Q4 2024 forecasts, stock rises Investing.com

Vir Biotechnology, Inc. (VIR) Stock Analysis: Navigating a 247% Potential Upside Amidst Challenges DirectorsTalk Interviews

Vir Lays Off 25% of Staff, Abandons Most Virus Work and Pivots to Cancer in Sanofi Deal BioSpace

Can investing in infectious disease pay off? Vir Biotechnology's tightrope walk shows it's a struggle statnews.com

Vir Biotechnology Could Be An Early Riser In 2025 With Oncology Data In January (VIR) Seeking Alpha

Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update BioSpace

Vir retreats from infectious disease; Vertex shelves AATD drugs BioPharma Dive

Vir's shares crater as influenza mAB flames out in 'disappointing' phase 2 result Fierce Biotech

Vir gains T-cell engagers from Sanofi, loses 25% of staff in another pipeline switch-up Fierce Biotech

Vir pressures Gilead with hepatitis D cocktail showing early efficacy in phase 2 Fierce Biotech

Vir Biotechnology announces results from SOLSTICE trial Nasdaq

GSK and Vir Biotechnology expand coronavirus collaboration to advance new therapeutics for influenza and other respiratory viruses GSK

Veteran biotech leader George Scangos to step down as Vir CEO BioPharma Dive

Brii Bio acquires Vir’s antibody rights for Hepatitis B in Greater China Pharmaceutical Technology

Vir, struggling to build on COVID success, says flu antibody fails key study BioPharma Dive

GSK and Vir Biotechnology enter collaboration to find coronavirus solutions GSK

VIR Stock Price and Chart — NASDAQ:VIR TradingView

Vir Biotechnology, San Francisco firm worth $1.3 billion, lays off 141 workers SFGATE

Vir Biotechnology and GSK announce VIR-7831 reduces hospitalisation and risk of death in early treatment of adults with COVID-19 GSK

GSK and Vir Biotechnology announce submission of Emergency Use Authorization request to FDA for VIR-7831 for the early treatment of COVID-19 GSK

Shares of Gates-backed Vir Bio tumble after $143M IPO to fund infectious disease efforts GeekWire

Evaluation of RNAi therapeutics VIR-2218 and ALN-HBV for chronic hepatitis B: Results from randomized clinical trials ScienceDirect.com

Is Vir Biotechnology Stock a Buy? The Motley Fool

Vir Biotechnology Appoints Jennifer Towne, Ph.D., as Executive Vice President and Chief Scientific Officer Business Wire

Publicly traded biotech firm to close Cortex office The Business Journals

Vir Biotechnology and GSK announce NHS-supported AGILE study to evaluate VIR-7832 in the early treatment of COVID-19 GSK

Vir’s GSK-Backed Flu Vaccine Candidate Fails Phase II Trial BioSpace

Vir Bio rides to $143m in IPO - Global Corporate Venturing

Vir Biotechnology and GSK announce start of NIH-sponsored ACTIV-3 trial evaluating VIR-7831 in hospitalised adults with COVID-19 GSK

Vir Biotechnology closes deal with Sanofi for T-cell engagers Pharmaceutical Technology

Bullish On Vir Biotechnology's Innovative Pipeline That Targets HIV And Hepatitis Seeking Alpha

Vir Biotechnology Announces Strategic Steps to Reduce Operating Expenses and Focus Investment on Areas with Highest Potential for Value Creation The AI Journal

Vir Biotechnology to Participate in the H. C. Wainwright 2nd Annual Hepatitis B Virus (HBV) Conference Yahoo Finance

VIR News Today | Why did Vir Biotechnology stock go up today? MarketBeat

Vir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024 The AI Journal

New Vir CEO Marianne De Backer on possibilities and visibility: ‘The right opportunity’ The Business Journals

SF biotechs cutting nearly 270 in The City San Francisco Examiner

Vir Biotech presents new data for functional cure of chronic Hep B virus Labiotech.eu

Vir Biotechnology: The First Entry In My Long Term Value Portfolio Seeking Alpha

Brii Biosciences Launches with $260 Million, a Partnership with Vir Biotech, and Other Relationships with WuXi and Alibaba BioSpace

Vir Biotechnology Launches To Cure, Treat, And Prevent Challenging Infectious Diseases Using Latest Advances In Immunology PR Newswire

Alnylam Jumps on $1B RNAi Pact With Vir Biotechnology BioSpace

Coronavirus: Bay Area biotech companies join race to test drugs, vaccines San Francisco Chronicle

Vir Biotech Jumps on New Drug Development Deal With GSK TheStreet

Fact-Check: Comedian Vir Das’ bio changed to “gang rapist” and “Abdullah” dfrac.org

57,268 Shares in Vir Biotechnology, Inc. $VIR Acquired by VIRGINIA RETIREMENT SYSTEMS ET Al Defense World